Larry C. Borish, MDa, Harold S

Slides:

Advertisements

Similar presentations

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Advertisements

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome Paul Steinberg, MDa, Bruce E.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Ulrich Wahn, MDa. ‡, Eli O. Meltzer, MDb. ‡, Albert F. Finn, MDc

Alalia Berry, MD, William W. Busse, MD

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction Robert A. Nathan, MDa, Jonathan A.

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children Mark Boguniewicz, MDa, Virginia C. Fiedler,

Asthma diagnosis and treatment: Filling in the information gaps

Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma Paweł Majak, MD, PhD, Błażej Rychlik, PhD, Łukasz Pułaski,

Richard L. ZuWallack, MD a,b, James P

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma Patrick Booms, MSca, David.

Overcoming barriers to nonadherence in asthma treatment

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers Harold S. Nelson, MDa, Kenneth.

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Badrul A. Chowdhury, MD, PhD

Multicenter, double-blind, placebo-controlled, multiple-challenge evaluation of reported reactions to monosodium glutamate Raif S. Geha, MDa, Alexa Beiser,

NAEPP Expert Panel Report

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

Adverse effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors associated with elevated serum IgE and eosinophilia Carol K. Fosso, MDa,

Harold B. Kaiser, MDa, Steven R. Findlay, MD†, John W

Mark T. S. Chan, MDa, Donald Y. M. Leung, MD, PhDb, Stanley J

Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients William W. Busse, MD, Sally E. Wenzel, MD, Eli O. Meltzer,

Elinor Simons, MDa, William M

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial William Busse, MDa,

Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with.

Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol Henry Milgrom, MDa, David P. Skoner,

Side effects of inhaled corticosteroids

Michael Mellon, MD Journal of Allergy and Clinical Immunology

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma Gail.

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model John M.

A review of the current guidelines for allergic rhinitis and asthma

Physician-targeted program on inhaled therapy for childhood asthma

Correlation between alcohol-induced asthma and acetaldehyde dehydrogenase-2 genotype Atsuko Takao, MDa, Terufumi Shimoda, MDa, Shigeru Kohno, MDa, Sadahiro.

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with.

Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses Raul E. Melo, MD, Dirceu Solé,

Jack M. Becker, MDa, Anjali Arora, MDb, Richard J

Clinical need for a nebulized corticosteroid

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients.

Thomas B. Casale, MDa, I. Leonard Bernstein, MDb, William W

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma Gordon D. Raphael, MDa, Robert.

News & Notes Journal of Allergy and Clinical Immunology

Fluticasone propionate powder: Oral corticosteroid–sparing effect and improved lung function and quality of life in patients with severe chronic asthma

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib Pär Gyllfors,

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy Diane J. Pincus, MD, Teresa R. Humeston,

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

National trends in asthma visits and asthma pharmacotherapy,

Airway remodeling-associated mediators in moderate to severe asthma: Effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MDa,

Desloratadine: A new, nonsedating, oral antihistamine

Presentation transcript:

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma Larry C. Borish, MDa, Harold S. Nelson, MDa, Jonathan Corren, MDb, George Bensch, MDc, William W. Busse, MDd, James B. Whitmore, PhDe, Jan M. Agosti, MDe Journal of Allergy and Clinical Immunology Volume 107, Issue 6, Pages 963-970 (June 2001) DOI: 10.1067/mai.2001.115624 Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 1 Mean percentage change from baseline in FEV1. Treatment with 3.0 mg of IL-4R after discontinuation of inhaled corticosteroids prevented decline in clinic-measured FEV1 (–2% with 3.0 mg of IL-4R vs –13% with placebo, ‡P = .05) over the 3-month treatment period. Journal of Allergy and Clinical Immunology 2001 107, 963-970DOI: (10.1067/mai.2001.115624) Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 2 Mean change from baseline morning FEV1 (in liters). Morning FEV1 was measured daily at home by using an Air Watch meter in the morning before β2-agonist therapy. Treatment with 3.0 mg of IL-4R after discontinuation of inhaled corticosteroids prevented decline in FEV1 (–0.1 L with 3.0 mg of IL-4R vs –0.5 L with placebo) over the 3-month treatment period. *P < .05 versus placebo. Journal of Allergy and Clinical Immunology 2001 107, 963-970DOI: (10.1067/mai.2001.115624) Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 3 Mean percentage change from baseline in evening FEV1. Evening FEV1 was measured daily at home by using an Air Watch meter at bedtime. Treatment with 3.0 mg of IL-4R after discontinuation of inhaled corticosteroids prevented decline in evening FEV1 (+3% with 3.0 mg of IL-4R vs –16% with placebo) over the 3-month treatment period. *P < .05 versus placebo, **P < .01 versus placebo. Journal of Allergy and Clinical Immunology 2001 107, 963-970DOI: (10.1067/mai.2001.115624) Copyright © 2001 Mosby, Inc. Terms and Conditions

Fig. 4 Mean percentage change from baseline in asthma symptom score. Patients treated with 3.0 mg of IL-4R at the time of discontinuation of inhaled corticosteroids had mean asthma score increases of 0.1 (42% change from baseline) versus an increase of 1.4 (204% change from baseline) in patients with placebo over the first month of observation (0-15 possible). ‡P = .07 versus placebo for percentage change. Journal of Allergy and Clinical Immunology 2001 107, 963-970DOI: (10.1067/mai.2001.115624) Copyright © 2001 Mosby, Inc. Terms and Conditions